Lipocine Financial Statements From 2010 to 2025

LPCN Stock  USD 2.97  0.02  0.68%   
Lipocine's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Lipocine's valuation are provided below:
Gross Profit
4.2 M
Profit Margin
(1.07)
Market Capitalization
16.1 M
Enterprise Value Revenue
0.6167
Revenue
4.2 M
We have found one hundred twenty available fundamental ratios for Lipocine, which can be analyzed and compared to other ratios and to its peers in the industry. Self-guided Investors are advised to check Lipocine's last-minute fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road. As of the 13th of August 2025, Market Cap is likely to drop to about 24.8 M. In addition to that, Enterprise Value is likely to drop to about 19.3 M

Lipocine Total Revenue

11.76 Million

Check Lipocine financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lipocine's main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 5.8 M or Total Revenue of 11.8 M, as well as many indicators such as Price To Sales Ratio of 2.21, Dividend Yield of 0.0 or PTB Ratio of 1.3. Lipocine financial statements analysis is a perfect complement when working with Lipocine Valuation or Volatility modules.
  
Build AI portfolio with Lipocine Stock
Check out the analysis of Lipocine Correlation against competitors.
To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.

Lipocine Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets29.4 M22.5 M25.2 M
Slightly volatile
Other Current Liabilities458.5 K482.6 K1.2 M
Pretty Stable
Total Current Liabilities1.4 M1.5 M2.7 M
Slightly volatile
Other Liabilities196.5 K206.9 K3.1 M
Slightly volatile
Accounts Payable258.1 K271.7 K623.6 K
Slightly volatile
Cash8.9 M6.2 M10.3 M
Pretty Stable
Cash And Short Term Investments26.4 M21.6 M22.6 M
Slightly volatile
Common Stock Total Equity10.7 K10.2 K4.3 K
Slightly volatile
Common Stock Shares Outstanding5.7 M5.4 M2.3 M
Slightly volatile
Liabilities And Stockholders Equity29.4 M22.5 M25.2 M
Slightly volatile
Other Current Assets539.5 K567.9 K1.2 M
Pretty Stable
Other Stockholder Equity154.2 M220.7 M132.3 M
Slightly volatile
Total Liabilities1.4 M1.5 MM
Slightly volatile
Total Current Assets28.5 M22.3 M24.5 M
Slightly volatile
Common Stock4.5 K8.9 K3.9 K
Slightly volatile
Property Plant Equipment124.4 K118.4 K69.2 K
Slightly volatile
Non Current Assets Total179.4 K188.8 K698.2 K
Slightly volatile
Capital Surpluse143.4 M251 M133.4 M
Slightly volatile
Property Plant And Equipment Gross1.5 M1.4 M511.9 K
Slightly volatile
Net Receivables114.4 K120.4 K343.7 K
Very volatile
Net Invested Capital27.2 M21 M22.4 M
Slightly volatile
Net Working Capital25.1 M20.8 M21.3 M
Slightly volatile
Short and Long Term Debt Total416.7 K438.6 K6.8 M
Slightly volatile
Long Term Debt Total4.3 M3.4 M5.6 M
Slightly volatile
Short and Long Term Debt2.5 M2.1 MM
Slightly volatile
Capital Stock7.6 K8.9 K4.6 K
Slightly volatile
Short Term Debt416.7 K438.6 K2.5 M
Slightly volatile
Current Deferred Revenue534.6 K288 K853.8 K
Slightly volatile
Non Current Liabilities OtherM1.2 M1.3 M
Slightly volatile

Lipocine Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative5.8 MMM
Slightly volatile
Other Operating Expenses15 M12.4 M12.9 M
Slightly volatile
Research Development9.1 M7.4 MM
Slightly volatile
Cost Of Revenue9.3 M7.4 M8.3 M
Pretty Stable
Total Operating Expenses13.8 M12.4 M11.8 M
Slightly volatile
Income Tax Expense6476816.1 K
Slightly volatile
Depreciation And Amortization43.2 K41.1 K25.7 K
Pretty Stable
Non Recurring582.9 K655.8 K715 K
Slightly volatile
Tax Provision426613604
Slightly volatile
Reconciled Depreciation43.2 K41.1 K23.9 K
Pretty Stable
Interest Income710.1 K1.1 M293.4 K
Slightly volatile

Lipocine Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
End Period Cash Flow9.8 M6.2 M11.3 M
Pretty Stable
Stock Based Compensation388.1 K408.6 KM
Very volatile
Begin Period Cash Flow4.5 M4.8 M10.9 M
Very volatile
Depreciation43.2 K41.1 K25.7 K
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Average Payables645 K833.8 K768.8 K
Slightly volatile
Capex To Depreciation3.932.19168.035
Slightly volatile
Payables Turnover25.7127.058745.008
Slightly volatile
Cash Per Share3.854.05219.781
Slightly volatile
Days Payables Outstanding17.4513.489236.7103
Slightly volatile
Current Ratio12.5314.753911.0151
Very volatile
Graham Number0.30.330.3649
Slightly volatile
Debt To Equity0.01980.02090.7114
Slightly volatile
Capex Per Share0.03210.01690.0249
Slightly volatile
Average Receivables82 K86.4 K224.7 K
Very volatile
Interest Debt Per Share0.0780.08225.087
Slightly volatile
Debt To Assets0.01850.01950.3185
Slightly volatile
Days Of Payables Outstanding17.4513.489236.7103
Slightly volatile
Long Term Debt To Capitalization0.140.150.3119
Slightly volatile
Total Debt To Capitalization0.01940.02050.3486
Slightly volatile
Debt Equity Ratio0.01980.02090.7114
Slightly volatile
Quick Ratio12.3914.753910.896
Very volatile
Net Income Per E B T1.090.92460.9965
Slightly volatile
Cash Ratio6.364.10195.6392
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.131.07381.0513
Slightly volatile
Debt Ratio0.01850.01950.3185
Slightly volatile
Gross Profit Margin0.330.34353.3155
Pretty Stable

Lipocine Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap24.8 M26.1 M57.8 M
Slightly volatile
Enterprise Value19.3 M20.3 M40.9 M
Very volatile

Lipocine Fundamental Market Drivers

Cash And Short Term Investments21.6 M

Lipocine Upcoming Events

8th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
8th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Lipocine Financial Statements

Lipocine investors utilize fundamental indicators, such as revenue or net income, to predict how Lipocine Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue288 K534.6 K
Total Revenue11.2 M11.8 M
Cost Of Revenue7.4 M9.3 M
Stock Based Compensation To Revenue 0.04  0.03 
Sales General And Administrative To Revenue 0.45  0.42 
Research And Ddevelopement To Revenue 0.66  0.62 
Capex To Revenue 0.01  0.01 
Revenue Per Share 2.10  1.99 
Ebit Per Revenue(0.10)(0.11)

Pair Trading with Lipocine

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lipocine position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lipocine will appreciate offsetting losses from the drop in the long position's value.

Moving against Lipocine Stock

  0.61ABBV AbbVie IncPairCorr
  0.37PFE Pfizer IncPairCorr
  0.35JNJ Johnson JohnsonPairCorr
  0.34GILD Gilead Sciences Sell-off TrendPairCorr
  0.33MRK Merck CompanyPairCorr
The ability to find closely correlated positions to Lipocine could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lipocine when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lipocine - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lipocine to buy it.
The correlation of Lipocine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lipocine moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lipocine moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lipocine can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Lipocine offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lipocine's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lipocine Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lipocine Stock:
Check out the analysis of Lipocine Correlation against competitors.
To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.
You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipocine. If investors know Lipocine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipocine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.84)
Revenue Per Share
0.787
Quarterly Revenue Growth
5.954
Return On Assets
(0.17)
Return On Equity
(0.24)
The market value of Lipocine is measured differently than its book value, which is the value of Lipocine that is recorded on the company's balance sheet. Investors also form their own opinion of Lipocine's value that differs from its market value or its book value, called intrinsic value, which is Lipocine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipocine's market value can be influenced by many factors that don't directly affect Lipocine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lipocine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lipocine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipocine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.